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Abstract:  
Background: Polycystic Ovarian Syndrome (PCOS) is a common, complex, 
endocrine condition with potential long-term cardiovascular, endocrine and metabolic 
health implications. Currently, there exists no medical treatment that addresses all 
clinical presentations. Herbal practitioners often treat women with PCOS; yet, there 
is a lack of research investigating PCOS and herbal treatment. This study aimed to 
examine the current scientific literature on PCOS and phytotherapy, explore 
practitioners’ experiences treating women with the syndrome and evaluate whether 
there is a role for phytotherapy in the treatment of PCOS. 
Methods: A literature search was conducted using the terms; ‘Polycystic Ovarian 
Syndrome’ / ‘PCOS’ and ‘phytotherapy’/‘herbal medicine’ / ‘herbs’. The published 
research identified by these terms was then reviewed. A brief questionnaire with a 
mix of eleven open and closed questions was sent to herbal practitioners on the 
National Institute of Medical Herbalists (NIMH) 2012 register. 
Results: The literature review found promising results for the use of Mentha spicata, 
Cinnamomum verum and berberine containing herbs. There was a weaker evidence 
base for the use of Glycyrrhiza glabra and Paeonia lactiflora. The questionnaire was 
completed by 72 practitioners, 71 % had treated women with PCOS. The majority 
(38%, n=50) felt herbal medicine was ‘quite successful’ in treating PCOS. The 
average time until herbal treatment started to be successful was 3.2 months. The 
most frequently used herbs were Paeonia lactiflora, Glycyrrhiza glabra and Vitex 
agnus castus. Dietary and lifestyle advice emerged as frequently identified 
therapeutic interventions. 
Conclusions: This exploratory study suggests that there is a role for phytotherapy in 
the treatment of PCOS. Further investigation, consisting of well-designed clinical 
trials and monitoring the successful use of herbal medicine by practitioners, is clearly 
necessary. This future research would serve to substantiate positive empirical 
evidence, constructing a more robust evidence base for the effective use of 
phytotherapy as a therapeutic option for women with PCOS. 
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1) Introduction 
 
‘Polycystic ovary syndrome is a frustrating experience for women, often complex 
for managing clinicians and a scientific challenge for researchers’ (Teede et al. 
2010, p1). 
 
    PCOS was first identified by Irving Stein and Michael Leventhal in 1935, whilst 
conducting a case study of seven women exhibiting the collection of symptoms of 
hirsutism, obesity, amenorrhea, and enlarged ovaries. Today, PCOS is recognised 
as a complex, heterogeneous, endocrine and metabolic condition with multiple 
aetiologies and clinical presentations with long term health implications. Although the 
exact aetiology is unknown, insulin resistance and compensatory hyperinsulinemia 
are now understood to play key roles (Dunaif, 1997). 
 
Definition and diagnosis: PCOS is one of the most common endocrine disorders in 
women of reproductive age. However, its definition and diagnosis remains 
controversial. The prevalence of PCOS is dependent on which definition is used; the 
National Institute of Health (NIH; 1990) at 6% or the Rotterdam (2003) at 15% 
(Fauser et al. 2012). 
 At present, the Rotterdam definition is the most widely accepted stating that 
women with PCOS will have a combination of two of the following: 
• Chronic anovulation 
• Clinical and/or biochemical signs of hyperandrogenism 
• Polycystic ovaries on ultra sound 
with the exclusion of other androgen excess or related disorders. These may include 
hyperprolactinema; abnormal thyroid function; non classical 2-hydroxylase deficiency 
and androgen secreting tumours.1  
 
 
 
 
                                                 
1 Chronic anovulation can be defined as absence of ovulation. Clinical signs of hyperandrogenism may include 
include hirsutism, alopecia, acanthosis nigricans and acne. Biochemical signs of hyperandrogenism include 
raised levels of androgens. Polycystic ovaries are defined as presence of 12 or more follicles in each ovary 
measuring 2±9 mm in diameter, and/or increased ovarian volume (>10 ml) 
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The NIH definition is the strictest, whilst the Rotterdam incorporates a broader 
spectrum of symptoms, notably polycystic morphology and the inclusion of women 
with hirsutism and regular menstruation. The Androgen and PCOS Society (Azziz et 
al. 2006) have proposed a further definition which concentrates on androgen excess. 
Of note is the fact that the choice of finition used subsequently affects the validity of 
the outcomes of clinical trials and research analysis (Welt 2006, Di Marcantonio 
2008). 
Standard biochemical tests to assist in the diagnosis of PCOS measure total 
testosterone, free testosterone, dehydroepionadrosterone (DHEA), glucose 
tolerance, insulin sensitivity, cholesterol, thyroid hormones and prolactin. Sex 
hormone binding globulin (SHBG) is sometimes tested. Historically, luteinising 
hormone (LH) and follicle stimulating hormone (FSH) ratios were tested but are 
rarely used now due to their poor specificity (Dunaif 1997). 
Recently there have been calls to change the name of PCOS as it has been 
perceived as confusing to both women with the syndrome and healthcare providers 
(Dunaif and Fauser, 2013). It has been proposed to re-name the syndrome to reflect 
the broader clinical significance and enhance recognition of its multi-faceted features 
(Teede et al. 2014 
 
Aetiology: The aetiology of PCOS remains elusive as currently there are no specific 
genetic or metabolic markers. However, there is evidence of a genetic link in first 
degree female relatives (Kashar-Millar et al. 2001) and that physical and 
environmental factors, such as obesity, nutrition and pollutants may be influential 
(Kandaraki 2009).  
Pathophysiology: The pathophysiology is not well established. Different ideas on its 
development may well be interlinked: 
• Metabolic derangements leading to insulin resistance and hyperandrogenism. 
• A primary neuroendocrine defect leading to elevated LH, Gonadotrophin 
releasing hormone (GnRH) pulse frequency and amplitude. 
• Inflammation and role of adipose tissue: adipokines, adiponectin and resistin, 
hormones that are secreted by adipose tissue have been indicated in the 
pathogenesis of PCOS (Carmina et al. 2005). 
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Insulin resistance resulting in hyperinsulinemia was first identified by Burghen 
(1980) as playing a key role in the pathogenesis of PCOS. Dunaif (1997) developed 
this finding to show that insulin resistance has a variety of circulatory, metabolic, 
hormonal and inflammatory consequences on the body. Hyperinsulinemia is 
understood to be the pathogenic mechanism involved in the development of 
hyperandrogenism. High levels of insulin stimulate the ovaries and adrenals to over 
produce androgens. This results in the absence of ovulation and consequent 
hyperandrogenism. Hyperinsulinemia decreases the hepatic production of the sex 
hormone binding globulin, which in turn further increases the amounts of circulating 
androgens. Insulin resistance is present in skeletal muscle and adipose tissue. With 
PCOS, there are defects in both insulin action and secretion and the molecular 
mechanisms differ from those found in obesity and NIDDM (Dunaif 1997). The GnRH 
frequency in the hypothalamus is higher than normal. This results in increased levels 
of LH relative to FSH. This hormonal imbalance further results in increased levels of 
androgens. 
  
Clinical manifestations: PCOS is often multifactorial in terms of signs and 
symptoms and these may vary in character and intensity during the different stages 
of a woman’s lifetime.  
• Anovulatory infertility: 50-70% of women with anovulatory infertility have 
PCOS (Pangariuan 2011). Approximately 90%–95% of anovulatory women 
presenting to infertility clinics have PCOS (Sirmans and Pate, 2014). The 
economic burden of diagnosing and treating this is estimated to be up to £22 
million annually in the UK (University of Nottingham PCOS Research Group, 
2014).   
• Amenorrhea, or oligomenorrhea: Up to 95% of affected women may have 
oligio or amenorrhea (Kumareplel et al. 2008). 
• Hirsutism: Occurs in approximately 60% of cases; however this varies with 
race and degree of obesity (Azziz et al. 2006). 
• Hyperinsulinemia: Reported in 50-80% of women with PCOS (Legro, 2004). 
Data further suggests that the severity of fasting hyperinsulinemia is 
associated with the severity of the clinical phenotype of hyperandrogenism, 
independent of obesity (Diamanti-Kandarakis et al.1999). 
• Dyslipidemia: Women with PCOS are 1.5-2.0 more likely to have 
dyslipidemia than age matched controls (Azziz, 2007). The most frequently 
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observed pattern consists of high triglycerides, high low-density lipoprotein 
(LDL) and low high-density lipoprotein (LDL), a similar biochemical pattern to 
NIDDM and associated with insulin resistance (Brunzell and Ayydei, 2003). 
• Obesity: Estimated that 50% of women with PCOS suffer from obesity (Azziz 
et al. 2004). It is an important factor in the development and complications of 
the syndrome; worsening insulin resistance and exacerbating reproductive 
and metabolic features (Balen 1995). Central adiposity is a particular feature 
of PCOS, even in normal weight women (Garruti 2009).This can be evaluated 
using weight to hip ratio (WHR) calculations.  
• Acne: Reported in 38% of women with PCOS (Borgia 2004). 
• Acanthosis nigricans (AN): One study found a 23% prevalence 
(Sivayoganathan et al. 2011). It is more common in South Asian women and 
strongly associated with insulin resistance.  
• Male pattern alopecia: One study found a prevalence of 16% in women with 
PCOS (Sivayoganathan et al. 2011) 
• Obstructive sleep apnoea (OSA): The risk for OSA is 5-10 times higher than 
in obese women without PCOS and is linked to an increase in adverse 
cardiovascular events (Ehrmann et al. 2012).  
• Anxiety and depression: More prevalent in women with PCOS. However it 
remains unclear whether this is due to the pathophysiology of the syndrome 
or as a consequence of the symptoms (Deeks 2012). 
 
Phenotypes of PCOS: An important new focus of research in the field of PCOS is 
the determination of the range of PCOS phenotypes. Phenotypes are a 
consequence of genotype combined with environmental factors such as diet, 
exercise, smoking, ethnicity, and age. Welt et al. (2006) found that women with 
PCOS characterised by regular menstruation and hyperandrogenism are the most 
severely affected in terms of insulin resistance and the consequential metabolic 
complications. Whereas Barber et al. (2007) found that those with normal androgen 
levels but polycystic ovaries and irregular menstruation had an almost normal 
metabolic profile in comparison to controls.  
This highlights the importance of identifying a women’s phenotype, screening 
appropriately and treating in response to the long term complications of the 
phenotype. This may help direct the focus away from debating PCOS definitions to 
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responding to the wide variations in which women with PCOS may present and any 
future health implications. 
 
Long term health implications: Women with PCOS have significant long term 
health implications. Sufferers have increased risk of developing; metabolic syndrome 
(Grundy et al. 2005); impaired glucose tolerance; gestational diabetes and non-
insulin dependent diabetes mellitus (NIDDM) (Dunaif 1997, Boomsma et al. 2006, 
Teede et al. 2010, Erhmann et al. 1999). Morgan et al. (2012) identified a threefold 
risk of young women with PCOS developing NIDDM.  Risk appears to be highest in 
women who have oligo/anovalation, hyperandrogenism and is amplified by obesity 
(Barber 2007). The prevalence of metabolic syndrome has been found to be higher 
in PCOS patients than in control women, 47% versus 4% (Dorkas et al. 2005). 
 Cancer risk remains a controversial area. Haoula (2012) and Chittenden 
(2009) identified a positive correlation with endometrial cancer, believed to be due to 
the effects of chronic anovulation and unopposed oestrogen exposure in the 
endometrium. Hardiman et al., in contrast, argue the evidence for the risk of 
endometrial cancer is incomplete; however, they acknowledge, that women with 
PCOS have certain risk factors that predispose them to developing the disease 
(Hardiman et al. 2003). There has been no confirmed correlation with breast, 
vaginal, vulval, cervical or ovarian cancers.  
Dyslipidemia is associated with PCOS (Wild, 2012) and Randeva and al. 
(2012) additionally identified a correlation between PCOS and an increased pro-
thrombotic state. However, the overall cardio-vascular disease (CVD) morbidity and 
mortality of PCOS patients remains unconfirmed, with conflicting evidence. Howlett’s 
et al. study (2012), over a 20 year period found an increased risk of myocardial 
infarction (0.2% to1.9%) and angina (0.8% to 2.5%) in age matched controls. 
Whereas Schmidt et al. (2012), in a 21 year follow up of PCOS patients, found no 
increase in stroke or myocardial infarction in comparison to controls. However, the 
sample size and controls are not directly comparable due to the large sample size in 
Howlett’s, (PCOS, n=2,353) and controls (n=432,506) and small sample size in 
Schmidt’s (PCOS, n=32) and controls (n=95). Nevertheless, both sets of research 
confirm the increased dyslipidemia observed in women with PCOS. However the 
data on the frequency of primary CVD events in women with PCOS remains 
inconclusive. There is a paucity both of long-term data for well-characterized women 
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with PCOS, and for large-scale prospective clinical trials to determine the outcome 
morbidity and mortality of CVD in PCOS subjects. 
As established, there are significant health risks that may impact morbidity 
and mortality. The health economic burden of PCOS in the USA has been estimated 
as ranging from $ 93 million to $ 1.77 billion annually (Azziz et al. 2005). 
Unfortunately, comparative statistics are currently unavailable for the UK. Experts 
agree that more cohort and longitudinal studies are urgently needed to confirm the 
long term consequences of PCOS, evaluate risk and construct effective screening 
programs. Timely diagnosis, treatment and lifestyle modifications can be very 
effective in minimizing these complications (Bargiota et al. 2012, Teede et al. 2010). 
 
Current medical treatment strategies 
 
‘There is currently no ideal medical PCOS therapy that fully reverses 
underlying hormonal disturbances and treats all clinical features’ (Teede et al. 2010, 
p6). 
 The wide variability in expression of the phenotypes of the syndrome 
continues to present diagnostic and treatment challenges. Medical treatment of 
PCOS is often symptom dependent, and in particular, directed at the clinical 
manifestations that women feel affect them most at that point of their life.  
 
Below are the traditional medical treatment options for women with PCOS,  
• Oral contraceptive pill (OCP): is the mainstay of treatment for 
menstrual irregularity and hyperandrogenism for those not wishing to 
conceive (BMJ, 2012). However emerging evidence suggests that the 
oral contraceptive may have negative effects on the metabolic 
aberrations of PCOS (Bargiota 2012). 
• Progestins: such as Medroxyprogesterone acetate (MPA), these are 
synthetic variants of progesterone. They are used primarily for 
dysfunctional uterine bleeding and hirsutism. However they can cause 
side effects such as weight gain, fluid retention, liver dysfunction and 
depression (Romm, 2010) 
• Anti-androgens: such as cyproterone acetate, spironolactone or 
flutamide are used in women with PCOS primarily to treat hirsutism. 
They are most often prescribed with the OCP due to the risk of fetus 
Page 9 of 40
Ac
ce
pt
ed
 M
an
us
cr
ipt
9 
 
feminisation in pregnancy and are therefore not appropriate for women 
seeking fertility outcomes.  
• Insulin sensitizing drugs: Metformin has emerged as the most 
effective new treatment in respect of hyperinsulinemia and its 
metabolic consequences, with some suggesting a long awaited cure for 
women with PCOS. However, recent investigation by Tang et al. (2012) 
has identified that it is of no benefit in improving weight loss, insulin 
sensitivity, nor lipid profiles in women with PCOS. Additionally, some 
women may suffer debilitating gastrointestinal disturbance and rarer 
complications of renal impairment and lactic acidosis (Teede at al. 
2007). 
• Clomiphene: Legro (2007) found that this was more successful than 
metformin in regards to live birth rate in women seeking fertility 
outcomes. Whereas a recent meta- analysis found no difference in 
success rate between the two (Palomba 2009). 
• Lifestyle changes: advocated as a first line evidence based approach 
for those women with PCOS who are overweight (Moran et al. 2009). 
Some patients with PCOS can resume menstrual cycles and ovulation 
after having reduced only 5% of their body weight (Kiddy et al. 1992). 
 
Emerging medical options; 
• Statins: recent research has indicated statins may be a treatment for 
PCOS, reducing hyperandrogenism and improving lipid profile (Duleba 
2012). However this therapeutic intervention remains a controversial 
option due to their potential side effects. 
 
Prescribed medications for PCOS often have significant side effects and 
contraindications. This proves especially problematic for women wishing fertility 
outcomes and those prescribed long- term medication. Additionally, some of the 
therapeutic interventions, although beneficial for some of the aberrations, might 
exacerbate others (Bargiota et al, 2012).  
Women with PCOS may present to gynaecologists, primary care physicians, 
endocrinologists, dermatologists, or other health care professionals, due to the wide 
variability of symptoms. Consequently, symptoms are often viewed and treated in 
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isolation, rather than as interlinked manifestations of this complex endocrine and 
metabolic medical syndrome. 
Results from a questionnaire of 648 women with PCOS (Sills et al. 2001), 
suggest that medical treatment frequently falls short of patients’ expectations. ‘The 
investigation detected a strong receptiveness among PCOS women regarding any 
safe and effective alternative to PCOS management’ (Sills, 2001, p8). 
 
Herbal medicine and PCOS 
 
Medical herbalists are health care providers trained in Western orthodox 
medical diagnosis that use unpurified plant extracts containing numerous 
phytochemicals to treat their patients. They use a poly-pharmacy approach, 
combining different herbs in each prescription (Pal and Shukalr, 2003). Each 
prescription is different and adapted to the individual patient rather treating a 
determined condition. Lifestyle and nutritional recommendations are important 
aspects of a medical herbalist’s treatment plan which takes an integrated and holistic 
approach. The traditional treatment strategies a medical herbalist may follow when 
treating a women with PCOS include: reducing insulin resistance; initiating ovulation 
and regulation of the menstrual cycle; decreasing androgens; improving hirsutism; 
supporting adrenal function; supporting liver function and reducing CVD risk.  
Throughout history, herbal medicine has been used to treat symptoms related 
to PCOS. Today, successful results are frequently reported by both practitioners and 
patients. Nevertheless, there remains a significant lack of scientific research 
validating the use of herbal medicine in the treatment of PCOS. Producing high 
quality herbal research is challenging due to the lack of uniformity in herbal 
prescriptions and additionally, sourcing funding. Chinese herbal medicine (CHM) has 
benefitted from more robust scientific interest, in particular with PCOS related 
infertility (Zhang et al. 2010, Kuek at al. 2011). Some of the herbs used in CHM, are 
incorporated into Western herbal medicine but often in very different formula so 
limited information may be extrapolated.  
There exist a limited number of reviews on the treatment of PCOS with 
phytotherapy (Hywood, 2012; Trickey, 1999; Hywood and Bone, 2004; Nagarantha 
2014), however, there are no comprehensive reviews of published research on the 
subject nor surveys of practitioners’ experiences treating the syndrome. 
 
Page 11 of 40
Ac
ce
pt
ed
 M
an
us
cr
ipt
11 
 
 Research Aim 
  The main aim of this study was to evaluate whether there is a role for 
phytotherapy in the management of PCOS. Current literature on PCOS and 
phytotherapy was reviewed and results compared with the experiences of medical 
herbalists who have treated women with the syndrome. 
Robust empirical evidence combined with high quality research will provide a 
stronger evidence base for the herbal practitioner to successfully treat women with 
PCOS. Additionally, successful results from herbal treatment may serve to direct 
areas of future scientific research. 
 
 
2)     Methodology 
 
2.1) Literature review of PCOS & Herbal Medicine 
Search strategy: The electronic search incorporated only those papers identified by 
the terms, [Polycystic Ovarian Syndrome’ or ‘PCOS’] and [herbal medicine’ or ‘herbs’ 
or ‘phytotherapy] on Science Direct and MEDLINE databases, between July and 
September 2012, published from 1980 in English. An update of the research was 
reviewed in May 2014. 
 
2.2) Practitioner survey 
Participants were qualified medical herbalists who were listed on the National 
Institute of Medical herbalists register of qualified members, 2012-13. An anonymous 
survey platform was utilized to distribute the questionnaire: Surveygizmo 
(www.surveygizmo.com). Participants were emailed inviting them to take part in the 
questionnaire, accessed through a hyperlink. The final version was distributed on 
July 18th 2012 to 428 contacts. The sampling procedure was classified as volunteer 
sampling and was essentially self-selecting.  
The questionnaire consisted of a mixture of open and closed questions to yield a 
combination of qualitative and quantative data; 
• Enquiring if the practitioner had treated PCOS 
• Practitioner reported success rate 
• Duration of treatment 
• Three most frequently prescribed herbs for PCOS 
• Other concurrent medication 
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• Additional diet and lifestyle advice 
• Views on PCOS and relationship to insulin resistance 
• Other treatment strategies 
Complete questionnaire (Appendix 1). 
 
Data analysis methods: Descriptive statistics illustrate the majority of the data 
collected. However, a Spearman’s rank correlation co-efficient was chosen as a form 
of inferential statistics. 
 
 
3) Results 
 
3.1)  Literature review: Herbal medicine and PCOS 
A total of 9 studies were selected ranging from animal models to randomized 
placebo controlled trials. The review identified papers in direct relation to PCOS and 
herbal medicine rather than researching herbs by action that may be appropriate in 
the treatment of PCOS. All studies identified by the search terms were included. Of 
note, no papers were identified specifically addressing the treatment of PCOS with 
Western herbal medicine. 
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Table 1: To show results of the literature review: Phytotherapy and PCOS: 
Search terms: ‘PCOS’ and ‘phytotherapy’/‘herb’/’herbal medicine’ 
Herb Research Study 
design and 
duration 
Main effects Comments 
Aloe 
barbadensis 
Mill. 
(Aloe Vera) 
Maharjan 
et al. 2010. 
Rat trial 
versus 
placebo in 
Letrozole 
induced 
PCOS rats. 
Reduced glucose 
levels. 
Hypolipidemic. 
Restored ovarian 
cycle. 
Prevented 
development of 
PCOS phenotype. 
Animal model and results may 
not necessarily reflect those of 
human subjects. 
Promising area for future 
human research. 
 
 
Berberine. 
(A constituent 
of Hydrastis 
candensis, 
Berberis 
spp., Coptis 
chinensis)  
Wei et al. 
2012. 
Randomized, 
placebo-
controlled 
trial. 
 
89 women 
with PCOS 
and insulin 
resistance. 
 
3 months 
Berberine +
cyproterone 
acetate (CPA) 
reduced waist 
circumference, 
WHR, cholesterol, 
TG, LDL. 
Increased HDL and 
SHBG versus 
METFORMIN+ 
CPA 
 
Berberine+CPA 
reduced WHR, 
fasting insulin, 
fasting plasma 
glucose, LDL,TG 
Increased HDL, 
SHBG versus 
PLACEBO.  
Only shows results whilst 
concurrently taking medication.
However promising in terms of 
future research. 
Larger trial would be welcome. 
Would be useful to research 
berberine containing herbs 
alone versus placebo.  
 
Proposed action: insulin 
sensitizer  
Cinnamomu
m verum 
(Cinnamon) 
Wang et al. 
2007. 
Pilot placebo 
trial. 
15 women 
with PCOS. 
8 weeks. 
Cinnamon 
extract 1g a 
day. 
Significantly 
increased insulin 
sensitivity to levels 
of normal women. 
 
Small sample size and short 
duration. 
Area of important further 
research 
Larger trial would be welcome 
Proposed action: insulin 
potentiating 
Glycyrrhiza 
glabra 
(Liquorice) 
Armanini et 
al. 2007. 
32 women 
with PCOS. 
  
3 months.  
 
Glycyrrhiza 
glabra plus 
spirolactone 
vs. 
spronlactone 
alone. 
 
Reduced incidence 
of metrorrhagia. 
Blood pressure 
significantly 
reduced during 
spironolactone 
treatment, while no 
change in 
Glycyrrhiza 
treatment. 
 
No symptoms 
related to volume 
depletion with 
treatment with 
Glychyrrhiza vs 
20% with 
Spironlactone 
alone. 
 
Small sample size and short 
duration. 
 
The two compounds have 
opposite effect on 
mineralcorticoid effector 
mechanism.  
 
Useful research for using 
pharmacological drugs and 
herbs concurrently.  
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Labisia 
pumilla var. 
alabata 
Mannerasa 
et al. 2010 
PCOS 
induced rats. 
Increased insulin 
sensitivity 
Reduced TG, 
cholesterol levels 
increased 
circulating resistin 
levels and 
decreased mRNA 
expression. 
Increased uterine 
weight indicating 
oestrogenic effects 
Animal model and results may 
not necessarily reflect those of 
human subjects. 
 
Encouraging results, area for 
further human research 
 
Proposed actions: insulin 
sensitizer, 
oestrogenic 
Mentha 
spicata 
(Spearmint) 
 
 
 
 
 
 
Mentha 
spicata 
Akdogan et 
al. 2007. 
 
 
 
 
 
 
 
Grant 
2010. 
12 hirsute 
women with 
PCOS. 
5 days. 
Tea twice a 
day during 
follicular 
phase. 
 
RCT. 
 
42 hirsute 
women with 
PCOS. 
30 days. 
 
Tea twice a 
day. 
 
Decreased 
testosterone 
Increased LH, FSH 
and oestradiol. 
 
 
 
 
 
Free and total 
testosterone 
reduced. 
 
Hirsutism reduced 
as perceived by the 
women but not 
utilizing the 
Ferriman Galway 
score. 
 
 
Very small preliminary trial. 
Short duration. 
 
 
 
 
 
 
Good quality RCT with 
encouraging results.  
Much larger and longer trial 
welcome. 
Author proposes trial not long 
enough to show significant 
difference by FG score due to 
slow hair follicle turn over time. 
Proposed action: anti-
androgen. 
Paeonia 
radix/ 
Paeonia 
lactiflora/ 
Cinnamonu
m spp. 
Combination 
(White 
peony and 
Cinnamon) 
Ushiroyam
a et al. 
2001. 
100 patients 
with PCOS 
(n=38) or 
non-
PCOS(n=62) 
were 
allocated 
randomly 
into two 
groups 
 
Japanese 
formula 
‘Unkei-to’. 
 
8 weeks. 
The mean rate of 
reduction of serum 
LH was 22.2 +- 
35.7% in polycystic 
ovary syndrome 
patients and 49.7 
+- 15.3% in non-
polycystic ovary 
syndrome patients. 
This reduction was 
significant in the 
non-polycystic 
ovary syndrome 
patients (P = .030). 
 
The rate of 
menstrual regularity 
was improved by 
50% (n=19) in 
PCOS group. 
 
 
 
Small sample size and short 
duration. 
 
Combined formula, difficult to 
extrapolate individual herbs 
effects. 
 
Unkei-to induced significant 
decreases in plasma LH in 
polycystic ovary syndrome and 
non-polycystic ovary syndrome 
with high LH levels. 
  
Stachys 
lavandulifoli
a 
(Wood 
betony) 
 
Jalilian, N. 
et al.,2013 
66 women 
with PCOS. 
 
RCT. 
 
3 months. 
 
Compared 
 Age‐adjusted 
prevalence rate of 
different patterns of 
AUB, decreased 
from 2.7 (95%CIs: 
0.6–48.0) to 1.1 
(95%CIs: 0.1–18.3) 
for patients taking 
Small sample size and short 
duration. 
In this trial, ABV has similar 
level of effectiveness in 
treating AUB as MPA, however 
adverse events were reported 
more frequently. 
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treatment 5g 
aerial parts 
wood 
betony(ABV) 
TID 
 
With 10mg 
BD of MPA 
for 3 cycles. 
 
MPA, and from 2.5 
(95% CIs: 0.2–
40.2) to 0.7 
(95%CIs: 0.0–12.1) 
taking ABV. 
 
However, Adverse 
effects were 
observed less 
frequently (24.2%) 
among participants 
on MPA than 
among those on 
AWB (45.5%). 
Key to abbreviations in Table 1 
AUB Abnormal uterine bleeding 
FSH Follicle stimulating hormone 
FG Ferriman Galwey score ( used to clinically rate degree 
of hirsutism) 
HDL High density lipoprotein 
LDL Low density lipoprotein 
LH Luteinising hormone 
MPA Medroxyprogesterone acetate 
SHBG Sex hormone binding globulin 
TG Triglycerides 
RCT Randomised controlled trial 
WHR Waist hip ratio 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Page 16 of 40
Ac
ce
pt
 
pt
16 
 
3.3)  Results of the herbal practitioner questionnaire 
 
The response rate was 17%; 72 responded out of a total of 428 contacts, 9 
unsubscribed from the questionnaire. A total of 72 practitioners completed the 
survey, 51 had treated women with PCOS giving a 71% treatment rate. The 
prevalence of symptoms for which patients sought treatment is illustrated by Fig. 1 
below. 
 
Figure 1: Bar chart to show symptoms for which patients presented for 
treatment (*other see Appendix 4) 
N=250, Menstrual irregularity= 49, Hirsutism =38, Acne= 38, Weight gain= 33, 
Infertility=33, Low energy=22, Low mood= 22, Other = 8, Alopecia= 7 
Note: practitioners may have identified more than one symptom 
 
 
Diet and lifestyle advice 
A variety of dietary and lifestyle advice was given by practitioners. The most 
common theme that emerged was that ‘diet is of fundamental importance in 
managing PCOS,’ followed by taking regular exercise, and avoiding refined sugar. 
Managing stress levels, increasing vegetable intake and following low glycaemic 
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index (GI)/glycaemic load (GL) diet were cited as subsequently important 
recommendations. 
Treatment strategies 
In terms of additional information and themes identified in the treatment of 
PCOS, hirsutism was cited as the most difficult to treat by eight of the respondents. 
The next most frequent recommendation was to consider each patient as unique. 
Subsequently, weight loss was identified as an important recommendation to reduce 
symptoms of PCOS. 
 
Herbs prescribed by practitioners in the treatment of PCOS 
 
Table 2: Showing practitioners choice of the three most frequently prescribed 
herbs and their formulation (Top three are highlighted) 
HERB Part used Tincture Fluid 
extract 
Juice 
bark  
Capsule Total times 
identified 
Paeonia lactiflora Radix 37  2   39    
Glycyrrhiza glabra  Radix 28 3 1  32 
Vitex agnus castus  Fructus 19 2   21 
Taraxacum officinalis Radix 4 1   5 
Chamaelium luteum Radix 3 2   5 
Galega officinalis Herba 3 1  1 5 
Angelica sinensis Radix 5    5 
Serenoa repens Fructus 3    3 
Centella asiatica Herba  3   3 
Achillea millefolium  Herba 3    3 
Silybum marianus Semen 2   1 3 
Cinnamonum verum Cortex 3    3 
Urtica diocia Folia and radix 2    2 
Gymnema Silvestre Folia 2    2 
Trigonella foenum- 
graecum 
Semen 1 1   2 
Cimicifugia 
racemosa 
Radix 2    2 
Lamium album Herba 1    1 
Scutellaria lateriflora Herba 1    1 
Eleuthrococcus 
senticosus 
Radix 1    1 
Phytolacca 
Americana 
Radix and 
fructus 
1    1 
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Calendula officinalis Flos 1    1 
Rubus idaeus Folia 1    1 
Trifolium pratense Flos  1   1 
Mentha spicata Herba 1    1 
Artemesia arboratum Herba 1    1 
Chelidonium majus Herba 1    1 
Thuja officinalis Cortex 1    1 
Totals  126 16 1 3 146 
 
A total of twenty-seven herbs were identified from the questionnaire in response to a 
request for practitioners to state the three herbs they used the most in their treatment 
of PCOS (Table 2). Paeonia lactiflora, Glycyrrhiza glabra and Vitex agnus were 
identified as the most frequently prescribed herbs with the use of tinctures and fluid 
extracts being practitioners main choice of formulation.. 
 
Successful treatment and timing 
Fifty practitioners responded to the question on the success of their herbal 
treatment. 2% (n=1) reported a small improvement, 36% (n=18) reported a 
reasonable improvement, 38% (n=19) were quite successful and 24% (n=12) were 
very successful. 
Practitioners were asked that if their herbal treatment was successful, what 
length of time this took. Responses ranged from 2 weeks to over 7 months. The 
mean length of time until start of successful treatment was 3.2 months and the 
standard deviation was 1.37. 
  
Statistical analysis 
A Spearman’s rank correlation co-efficient was undertaken; it found a positive 
relationship between success and duration of treatment, significant at p<0.10, the 
10% level. The level of significance value established was p =0.10, this is equivalent 
to r= 0.188.  
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Figure 2: A scattergram to show the relationship between the effectiveness 
and start of successful herbal treatment using a Spearman’s rank correlation 
co-efficient. (Series 1=practitioner values) 
 
Concurrent pharmaceutical medication 
Fifty practitioners responded to the question of whether patients were taking 
concurrent pharmaceutical medication during their herbal treatment. 45% (n=23) 
practitioners responded that their patients were taking concurrent pharmaceutical 
medication. The oral contraceptive and Metformin were most frequently cited, 
followed consecutively by Spironolactone, Finesteride and glucocorticoids. 
Insulin resistance 
Fifty-five practitioners responded to the question ‘Is insulin resistance a key factor 
in PCOS’.  82% (n=45) of practitioners agreed whilst 16% (n=9) felt neutral about 
this statement and 2% (n=1) disagreed. 
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4) Discussion 
 
The current study confirms that women with PCOS are seeking treatment for their 
symptoms from herbal practitioners. Of the seventy two respondents in the 
practitioner questionnaire, 71% (n=51) had treated women with this condition. 
National figures are unavailable for the treatment ratios of herbal practitioners; 
nevertheless, this preliminary study does suggest it is a condition many have treated. 
It would be valuable to quantify numbers of women with PCOS presenting to herbal 
practitioners and this could be achieved by conducting a national treatment survey.  
The questionnaire highlighted that the symptom patients presented with most 
frequently was menstrual irregularity (figure 1). Strowitzki (2010) showed that, in 
women with PCOS, menstrual irregularity is often a symptom of women with the 
most endocrine and metabolic abnormalities, and possible long term health risks. 
Consequently, it is important that herbal practitioners recognise the potential 
indications of this symptom in PCOS, and refer appropriately for further investigation 
to rule out associated endocrine and metabolic pathologies.  
The second most common symptom was hirsutism. Thematic analysis of 
practitioners’ responses suggests that it may be the most problematic to treat and 
may take the longest time ‘Hirsutism seems the hardest to deal with’ (Practitioner 
response, 2012). Patients should be made aware of this prognosis by the herbal 
practitioner when discussing their therapeutic treatment options. 
A key point that emerged from the questionnaire was that herbal practitioners 
are in an important position to assist in the diagnosis of women with undiagnosed 
PCOS. In fact, one participant stated, ‘I have often been the first to pull disparate 
symptoms together and offer a diagnosis’ (Practitioner response, 2012). In a recent 
community study, 69% of women with PCOS did not have a pre-existing diagnosis 
(March et al. 2010). Herbal practitioners are in a strategic position to identify 
disparate symptoms, formulate a working diagnosis and refer to the patient’s doctor 
for confirmation with the benefit of biochemical analysis and ultra-sound imaging. 
Taking an integrated approach incorporating herbal practitioners, GP’s and other 
healthcare practitioners may provide a better diagnostic service for women with 
PCOS. 
The majority of the practitioners report their treatment of women with PCOS 
was ‘quite successful’ and the average time until start of successful treatment was 
3.2 months. Although a significance level of p=0.05 is typical in scientific papers, this 
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tentative evidence does suggest that the longer a patient has herbal treatment, the 
more successful it will be. Practitioners may want to incorporate this finding into their 
prognosis for women with PCOS (Figure 2) 
A confounding variable was that many patients treated by practitioners may 
have been concurrently taking pharmaceutical medications. Therefore, these results 
may have been in part due to the action of these drugs rather than herbal treatment. 
Additionally, it is important to clarify that the practitioner’s view of start of the 
successful treatment may vary from that of the patient. Future investigation into 
herbal treatment without concurrent medication, patient’s experiences of herbal 
treatment and biochemical analysis is necessary to substantiate these results. 
 
In the questionnaire, the most commonly used herbs by practitioners were 
Paeonia lactiflora, Glycyrhhiza glabra and Vitex agnus castus (Table 2).  
Paeonia lactiflora was the most popular choice. Pharmacological research has 
confirmed that paeoniflorin; a key constituent of Paeonia lactiflora significantly 
decreases testosterone production from the ovaries (Takeuchi et al. 1991). Overall, 
however, it has a limited evidence base for use, with the majority of evidence related 
to use in Chinese formulas, often combined with Glycyrhhiza glabra. Ruth Trickey, in 
her book, ‘Women, Hormones and the Menstrual Cycle’ (2004), recommends a daily 
formula of Glycyrrhiza glabra 1:1; Fluid extract; (3ml) and Paeonia lactiflora; 1:2; 
tincture; (7mls). This is based on Japanese research indicating this herbal 
combination decreases testosterone levels in women with PCOS (Takahashi et al. 
1994).  
Glycyrrhiza glabra was the second most popular choice. It has been reviewed 
in terms of PCOS in the literature review (Table 1). Other studies in non-PCOS 
women have shown it has an anti-androgenic action (Armanini at al. 2004) and 
suggested that this effect is due to the ability of the constituents of Glycyrrhiza glabra 
to block 17-hydroxysteroid dehyrogenase and 17-20 lyase. Pharmacological 
investigation on rats has shown that glycyrrhetinic acid, a constituent of Glycyrrhiza 
glabra significantly decreases testosterone production from the rats’ ovaries 
(Takeuchi et al, 1991). Further research suggests that glycyrrhetinic acid, increases 
circulating and therefore, salivary levels of unconjugated deoxycorticosterone and 
dehydroepiandrosterone by inhibiting their conjugation at source within the adrenal 
cortex (Al-Dujaili et al, 2011). This supports the hypothesis that it may be of value in 
the treatment of PCOS. Glycyrrhiza glabra has also been attributed to a reduction in 
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body mass during oral treatment (Armanini et al, 2003) which may be of benefit for 
those women with PCOS who are overweight. In high doses or during long term 
treatment, Glycyrrhiza glabra has the potential to increase blood pressure (Armanini 
et al, 2004); however, this was not highlighted as an issue by any of the practitioners 
in this questionnaire. 
The third most popular herb utilized by practitioners was Vitex agnus castus. 
Interestingly, there have been no large scale studies examining this herb in the 
treatment of PCOS published in the English language. This questionnaire finding 
suggests that this is a potentially effective treatment and a prominent herb for future 
investigation. Vitex agnus castus has been used therapeutically primarily for its 
dopamegic effects and in the treatment of pre-menstrual syndrome, corpus luteal 
insufficiency and latent hyperprolactinemia (Mills and Bone 2013). A small scale 
survey interviewed 12 practitioners using the herb for different female reproductive 
conditions (Burgoyne 2011). In this study most practitioners agreed that 3 to 6 
months treatment time was necessary to bring about any significant, lasting 
improvements. This finding mirrors the start of successful treatment results found in 
this questionnaire, adding weight to its role in the effective treatment of PCOS. 
Although there was no scientific research identified in the literature review, Vitex 
agnus castus presents a promising subject for future research projects, with 
successful empirical results in this and other studies. 
In terms of the literature review, Cinnamomum verum is well researched in 
comparison with many other herbs (Table 1), with particular focus on its 
hypoglycaemic and hypocholesteremic effects and as a potential treatment for 
NIDDM (Pham et al, 2007) and metabolic syndrome (Khan et al. 2003). Wang et al. 
(2007) have found that Cinnamomum verum extract has an insulin potentiating 
activity by increasing phosphatidylinositol 3-kinase activity that is present in the 
aqueous fraction. Cinnamomum verum appears to present promise in terms of 
treating insulin resistance and hyperinsulinemia which is characteristic of PCOS and 
additionally, to combat some of the longer term CVD consequences. Importantly, 
there have been no adverse effects reported in any trials to date and it is a 
commonly used culinary spice in many cultures. 
The potentially important role of ethnobotany in the development of herbal 
treatment for PCOS is illustrated by research on two herbs. Initial investigation was 
prompted by traditional use in their respective cultures for symptoms related to 
PCOS. Research into the herb Mentha spicata was guided by traditional use for 
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hirsutism in Turkey (Grant, 2012). A randomised controlled trial by Grant in 2010 
indicated that this herb had potential to be a beneficial treatment. In the 
questionnaire, its use was documented by one practitioner however; a tincture was 
used rather than an infusion as used in the trial. The research into the herb Labisia 
pumilla var albta has also been directed by traditional use of the herb in Malaysia for 
infertility and menstrual disturbances (Manneras et al. 2010) Research to date has 
only been in rat models but results seem promising as a potential future treatment. 
The research on Stachys lavandulifolia indicates effectiveness in treating 
abnormal uterine bleeding in women with PCOS, however, the higher level of 
reported adverse events is noted which may affect its suitability for use with patients. 
A much longer and larger trial would be welcome to determine this.  
 Research on the use of Berberine containing herbs presents exciting promise 
for herbal treatment of women with PCOS. Berberine containing herbs include 
Hydrastis candensis, Berberis vulgaris, Berberis aquifolium. The research focuses 
on patients taking berberine concurrently with an anti-androgen medication, and 
shows hypoglycaemic and anti-hyperlipidaemic effects. Importantly, treatment with 
berberine decreased important risk factors for CVD disease, such as waist hip ratio, 
waist circumference, triglycerides, total cholesterol and LDL. Furthermore, reported 
adverse effects with berberine treatment were less than treatment with metformin. 
 The mechanism of action of berberine on women with PCOS are still unclear. 
Wu and al. (2006) found that berberine improved insulin resistance in theca cells and 
granuolsa cells in a similar way to metformin, by modulating androgen production 
through the activation of AMP-activated protein kinase. Therefore this may be an 
area for further research to determine this mode of action. A multicentre, 
randomized, placebo-controlled and double-blind trial has been registered (Yan et 
al., 2013) to evaluate the effects of berberine on insulin resistance in women with 
PCOS. Results of this may bring a stronger evidence base for the use of berberine in 
the treatment of PCOS 
Diet and lifestyle emerged as key areas for the practitioner to address in the 
treatment of PCOS. Part of the herbal practitioner’s role is to examine lifestyle and 
diet whilst taking the case history and to advise appropriately. Lifestyle change is the 
first line evidence based approach in women with PCOS who are overweight (Moran 
et al. 2009). Questionnaire analysis revealed low GI, GL and high protein diet were 
recommendations. Studies have shown that a low-carbohydrate, ketogenic diet can 
lead to weight loss and improvements in insulin resistance (Huber-Buchholz, 1999). 
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Weight loss, if appropriate, is also advocated by many herbal practitioners; 
confirmed by the scientific research (Kiddy 1992). 
There is increasing evidence that PCOS is not purely a gynaecological disorder 
but a complex endocrine disorder. The majority of practitioners questioned agreed 
that insulin resistance is a key factor in PCOS and this is reflected in the bulk of the 
scientific research (Dunaif 1997, Teede 2010). Many of the herbs chosen by the 
practitioners exert hypoglycaemic effects such as Cinnamomum spp. and Galega 
officinalis but interestingly, they were not the first three most frequently chosen 
herbs.  
A constant theme that emerged from the review of the literature on PCOS was 
patient dissatisfaction with pharmacological medical treatment. Metformin, has been 
heralded as a ‘cure’ for many of the symptoms of PCOS, but on closer examination, 
many women suffer debilitating gastro-intestinal side effects and are searching for 
alternative therapeutic options (Verity, 2012). In general, herbal treatment seemed to 
be well tolerated by women with PCOS. Side effects of herbal treatment did not 
emerge as an issue; although this may have been due to the practitioners not 
wanting to highlight this kind of information. 
 
Limitations of this research project: 
 
• The survey was distributed to NIMH members only, whilst the largest 
professional body in the UK it must be recognized that it only 
represents a fraction of the practitioners of Western herbal medicine. 
Consequently, the applicability of the results to the wider herbal 
community is unclear. 
• The numbers of PCOS patients treated by herbal practitioners was not 
quantified in this preliminary study making impact difficult to assess. 
• The response rate of practitioners was low, at 17%, however the other 
identified published survey with medical herbalists from NIMH using 
solely email surveys delivered a response rate of 16% (Brock et al, 
2012). Corp and Pendry (2013) utilized postal surveys as well as 
emails and had a response rate of 26%. Therefore the use of only 
email surveys in this study may have impacted on the overall response 
rate. 
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• The treatment success rate was taken whilst some patients were taking 
concurrent medications thus confounds the results since this was only 
taken from the practitioner’s viewpoint, which may be biased. 
 
Table 3: A table to show potential future areas of investigation identified in this 
research project. 
• Case study led interviews with herbal practitioners regarding treatment 
of patients with PCOS. 
• Questionnaires of women with PCOS being treated by herbal 
practitioners, their views on herbal treatment and the use of a validated 
symptom scale to monitor results. (Validation is important otherwise 
scales are not scientifically relevant). 
• National treatment survey of herbal practitioners to identify numbers of 
women with PCOS treated by herbal practitioners. 
• Study to investigate effectiveness of herbal treatment in women with 
PCOS wishing fertility outcomes. 
• New design of RCT using individualized herbal treatment utilizing 
herbal placebo formula and treatment (see Flower 2012). Results using 
validated symptom scales and biochemical tests. 
• Further investigation into the safety of herbs whilst taking concurrent 
medication, in particular, metformin. 
 
 
 
Conclusion 
 
This preliminary study concludes that phytotherapy shows a promising role in 
the treatment of PCOS. Empirical evidence from the questionnaire of herbal 
practitioners clearly confirms this, with frequent successful results identified.  
Evidence from scientific research of herbs in the treatment of PCOS is limited. 
However, there are some encouraging results that suggest some herbs may exert 
hypoglycaemic and anti- androgen actions beneficial in the treatment of PCOS. 
Some herbs may additionally, offer cardio- protective benefits reducing long term 
CVD risk which is becoming increasingly recognised as a significant risk factor for 
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women with PCOS. Further research is clearly necessary to substantiate these 
preliminary results.  
Herbal treatment appears to offer a valid potential therapeutic option for 
women with PCOS. Herbal formulae, prescribed by the herbal practitioner, provide a 
multi-target treatment approach, particularly suited to the disparate symptoms 
suffered by these women. Current medical treatment is limited by its narrow 
therapeutic approach and by the side effects of some medications. Many of the 
practitioners in the questionnaire offered detailed dietary and lifestyle advice that 
research has shown to be beneficial in outcomes of women with PCOS.  
The results of this study indicate potential benefits of phytotherapy as a 
therapeutic option for women, used both alone and concurrently with 
pharmacological treatment. This study indicates that further investigation into the use 
of phytotherapy in the treatment of women with PCOS is both justified and 
necessary.   
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Herbal medicine practitioner questionnaire investigating the treatment of PCOS 
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Appendix 
Appendix A: Herbal medicine practitioner questionnaire investigating 
treatment of PCOS 
 
1) Have you ever treated a patient/s with Polycystic Ovary Syndrome (PCOS)?* 
( ) Yes 
( ) No 
  
2) For which symptoms, related to PCOS, did your patient/s seek treatment? 
[ ] Hirsutism 
[ ] Menstrual irregularity 
[ ] Acne 
[ ] Low energy 
[ ] Weight gain 
[ ] Alopecia 
[ ] Infertility 
[ ] Other (Please specify: you may type more than one answer) 
  
3) What do you consider to be your three key herbs in the treatment of PCOS? 
Please type herb name in Latin and part in appropriate box (NB Herb choices 
are not in ranked order) 
  
Name of 
Herb 
Part used 
Herb 
1 
___  ___  
Herb 
2 
___  ___  
Herb 
3 
___  ___  
  
4) In what form do you prescribe these herbs? 
Please indicate the type of formulation/s you use in the appropriate box, i.e. 
tincture, infusion, powder 
 
Adminis
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erb tration Form 
1        ___  
2 ___  
3 ___  
 
 
  
5) In your experience, how effective do you feel herbal medicine is for the 
treatment of PCOS? 
( ) No change 
( ) Small improvement 
( ) Reasonable improvement 
( ) Quite successful 
( ) Very successful 
  
6) If the treatment was considered successful, how long did it take to work? 
( ) First week 
( ) 2-4 weeks 
( ) 2-3 months 
( ) 3-4 months 
( ) 4-5 months 
( ) 5-6 months 
( ) 6-7 months 
( ) 7 months and over ( please specify): _________________ 
 
  
7) Were any of your patients with PCOS receiving any concurrent orthodox 
medication for the treatment of PCOS? 
( ) Yes 
( ) No 
( ) Not sure 
  
8) If you answered yes to Q.7, please indicate which type of medication? 
[ ] Oral Contraceptive 
[ ] Spironolactone 
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[ ] Metformin 
[ ] Finasteride 
[ ] Glucocortocoids 
[ ] Other;please specify; you may add more than one 
  
9) Do you give any additional dietary and lifestyle advice for managing PCOS? 
  
10) Recent research has indicated that insulin resistance is a major factor in 
PCOS, do you agree with this? 
( ) Agree 
( ) Disagree 
( ) Neutral 
  
11) Any additional comments about PCOS/ herbal approaches/ management 
plans/ treatment outcomes? 
 
 
 
 
 
 
 
 
 
 
